In the video below, Motley Fool health-care analyst Max Macaluso takes a question from a Fool reader, who asks, "What do you think of AbbVie (NYSE: ABBV ) ?"
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.